TScan Therapeutics, Inc. (NasdaqGM: TCRX)
Health Care · Biotechnology · US
$0.78
+0.09% today · -59.0% 1Y
TScan Therapeutics, Inc. (NasdaqGM: TCRX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $52.83M and employs 139 people.
Over the last twelve months the share price has lost 59.0%, trading between 0.72 and 2.57.
Tweenvest scores TScan Therapeutics, Inc. across four factors: quality 26/100, value 47/100, growth 100/100. Its strongest factor is growth.
TCRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $52.83M
- Revenue (TTM)
- $7.11M
- P/E
- —
- EPS
- -1.74
- Dividend yield
- —
- Beta (5Y)
- 1.07
- 52-week high
- $2.57
- 52-week low
- $0.72
- Avg volume (3M)
- —
- Shares outstanding
- 67.78M
- Employees
- 139
- Next earnings
- —
About TScan Therapeutics, Inc.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
- Founded
- 2018
- Listed since
- Jul 16, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.31 | +0.51% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.00 | -1.43% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.